Breaking News

Sirnaomics Advances GalAhead-Based Drug Candidates Focused on Complement-Related Diseases

Among 4 candidates developed with GalAhead, 1 has entered into an IND enabling study, while the other 3 are moving into the candidate nomination stage.

Author Image

By: Charlie Sternberg

Associate Editor

Sirnaomics Ltd., a biopharmaceutical company, has advanced its GalAhead RNAi delivery platform for developing novel therapeutic products focused on complement-related diseases.   Among four product candidates developed with GalAhead, STP144G, which targets Complement Factor B, has entered into an IND enabling study, while the other three — STP146G, STP145G, and STP247G — are moving into candidate nomination stage.   Sirnaomics’ proprietary GalNAc-RNAi therapeutic platform, GalAhead, re...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters